SeaCrest Wealth Management’s Meridian Bioscience Inc VIVO Stock Holding History

SeaCrest Wealth Management’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,800	Closed	-$32K	–	2004
2019 Q1	$32K	Hold	1,800	–	–	0.01%	1097
2018 Q4	$31K	Hold	1,800	–	–	0.01%	1073
2018 Q3	$27K	Hold	1,800	–	–	﹤0.01%	1262
2018 Q2	$29K	Sell	1,800 -1,000	-36%	-$14.9K	0.01%	1208
2018 Q1	$40K	Hold	2,800	–	–	0.01%	1051
2017 Q4	$39K	Buy	+2,800	New	+$41K	0.01%	1066

Other funds holding VIVO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SFM

Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SeaCrest Wealth Management's VIVO Position: Q2 2019 in Review

SeaCrest Wealth Management sold out of Meridian Bioscience Inc (VIVO) in Q2 2019, closing a stake of 1,800 shares — an estimated $32K sold.

SeaCrest Wealth Management first reported a position in VIVO in Q4 2017 and held it in 6 quarters. The position peaked at $40K in Q1 2018. 173 funds tracked by Wall St. Rank hold VIVO as of Q2 2019.

SeaCrest Wealth Management reported no remaining Meridian Bioscience Inc position as of Q2 2019 after selling out during the quarter.
SeaCrest Wealth Management sold 1,800 Meridian Bioscience Inc shares in Q2 2019, an estimated $32K.
SeaCrest Wealth Management first reported a position in Meridian Bioscience Inc in Q4 2017 and held it in 6 quarters.
SeaCrest Wealth Management's Meridian Bioscience Inc position peaked at $40K in Q1 2018.
173 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q2 2019.

Based on SeaCrest Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.